Atara Biotherapeutics

ATRA65

$7.93arrow_drop_up0.76%$0.06

ATRA65

$7.93

arrow_drop_up0.76%$0.06

Performance History

There's no data available for key stats

There's no data available for ratios/profitability stats

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Atara Biotherapeutics (ATRA)

Atara Biotherapeutics Inc (ATRA) is a biotechnology company focused on developing therapeutics for patients with serious medical conditions. The company's primary focus is on developing novel allogeneic T-cell therapies for the treatment of cancer and autoimmune diseases. Atara Biotherapeutics is committed to improving patient outcomes and transforming the way these diseases are treated.

The stock price history of Atara Biotherapeutics Inc (ATRA) has seen both highs and lows over the years. Investors have closely followed the company's progress and the impact of its clinical trials on the stock price. The stock has experienced volatility due to market conditions and the release of key data. However, despite the fluctuations, Atara Biotherapeutics Inc has shown resilience and continues to be a company of interest for investors in the biotech sector.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Pascal Touchon D.V.M.
Headquarters: Thousand Oaks
Employees: 317
Exchange: NASDAQ

Keep an eye on Atara Biotherapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Atara Biotherapeutics 's (ATRA) price per share?

The current price per share for Atara Biotherapeutics (ATRA) is $7.93. The stock has seen a price change of $0.06 recently, indicating a 0.76% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Atara Biotherapeutics (ATRA)?

For Atara Biotherapeutics (ATRA), the 52-week high is $49, which is 517.91% from the current price. The 52-week low is $4.98, the current price is 59.4% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Atara Biotherapeutics (ATRA) a growth stock?

Atara Biotherapeutics (ATRA) has shown an average price growth of 0.41% over the past three years. It has received a score of 1 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Atara Biotherapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Atara Biotherapeutics (ATRA) stock price performance year to date (YTD)?

As of the latest data, Atara Biotherapeutics (ATRA) has a year-to-date price change of -33.9%. Over the past month, the stock has experienced a price change of 10.29%. Over the last three months, the change has been -10.9%. Over the past six months, the figure is -53.54%. Looking at a longer horizon, the five-year price change stands at -97.92%.

help

Is Atara Biotherapeutics (ATRA) a profitable company?

Atara Biotherapeutics (ATRA) has a net income of -$276.13M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -62.41% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $8.57M, although specific revenue growth data is currently not available. Operating income is noted at -$269.28M. Furthermore, the EBITDA is -$162.12M.

help

What is the market capitalization of Atara Biotherapeutics (ATRA)?

Atara Biotherapeutics (ATRA) has a market capitalization of $44.65M. The average daily trading volume is 125.71K, indicating the stock's liquidity and investor engagement.